Nivalis Therapeutics Inc. (NVLS) Downgraded to Neutral at Robert W. Baird
Robert W. Baird cut shares of Nivalis Therapeutics Inc. (NASDAQ:NVLS) from an outperform rating to a neutral rating in a report released on Tuesday morning. They currently have $3.00 price objective on the stock, down from their prior price objective of $29.00.
Other analysts have also recently issued research reports about the stock. Stifel Nicolaus cut shares of Nivalis Therapeutics from a buy rating to a hold rating and reduced their target price for the company from $16.00 to $3.25 in a report on Tuesday. Zacks Investment Research raised shares of Nivalis Therapeutics from a hold rating to a buy rating and set a $5.75 target price on the stock in a report on Saturday, November 5th. Cowen and Company reaffirmed a buy rating on shares of Nivalis Therapeutics in a report on Monday, August 1st. HC Wainwright reaffirmed a buy rating on shares of Nivalis Therapeutics in a report on Monday, August 8th. Finally, Piper Jaffray Cos. reaffirmed a buy rating and issued a $16.00 target price on shares of Nivalis Therapeutics in a report on Tuesday, August 30th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Nivalis Therapeutics currently has an average rating of Hold and a consensus price target of $9.00.
Shares of Nivalis Therapeutics (NASDAQ:NVLS) opened at 2.57 on Tuesday. Nivalis Therapeutics has a 52 week low of $3.68 and a 52 week high of $9.45. The firm’s market capitalization is $39.95 million. The firm’s 50-day moving average is $6.46 and its 200 day moving average is $5.84.
Nivalis Therapeutics (NASDAQ:NVLS) last issued its earnings results on Monday, November 7th. The company reported ($0.48) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.11. On average, equities analysts forecast that Nivalis Therapeutics will post ($2.10) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Nivalis Therapeutics Inc. (NVLS) Downgraded to Neutral at Robert W. Baird” was published by Financial Market News and is the propert of of Financial Market News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece can be accessed at http://www.financial-market-news.com/nivalis-therapeutics-inc-nvls-downgraded-to-neutral-at-robert-w-baird/1210519/.
In other news, EVP David Malcom Rodman sold 5,820 shares of the firm’s stock in a transaction that occurred on Tuesday, October 4th. The shares were sold at an average price of $7.96, for a total transaction of $46,327.20. Following the transaction, the executive vice president now directly owns 18,056 shares in the company, valued at $143,725.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 3.00% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. AXA raised its position in shares of Nivalis Therapeutics by 35.4% in the second quarter. AXA now owns 533,692 shares of the company’s stock worth $2,455,000 after buying an additional 139,652 shares during the period. Opaleye Management Inc. raised its position in Nivalis Therapeutics by 160.0% in the second quarter. Opaleye Management Inc. now owns 260,000 shares of the company’s stock worth $1,287,000 after buying an additional 160,000 shares during the period. BVF Inc. IL raised its position in Nivalis Therapeutics by 24.5% in the second quarter. BVF Inc. IL now owns 1,926,443 shares of the company’s stock worth $8,862,000 after buying an additional 379,700 shares during the period. Paloma Partners Management Co purchased a new position in Nivalis Therapeutics during the second quarter worth $105,000. Finally, Bank of New York Mellon Corp raised its position in Nivalis Therapeutics by 7.8% in the third quarter. Bank of New York Mellon Corp now owns 16,494 shares of the company’s stock worth $134,000 after buying an additional 1,189 shares during the period. Institutional investors and hedge funds own 79.26% of the company’s stock.
About Nivalis Therapeutics
Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.
Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.